The halogenation of natural flavonoids, baicalein and chrysin, enhances their affinity to human protein kinase CK2.
Antineoplastic Agents
/ chemistry
Casein Kinase II
/ antagonists & inhibitors
Cell Line, Tumor
Drug Screening Assays, Antitumor
Flavanones
/ chemistry
Flavonoids
/ chemistry
Halogenation
Humans
Magnetic Resonance Spectroscopy
Models, Molecular
Protein Kinase Inhibitors
/ chemistry
Structure-Activity Relationship
CK2 kinase inhibition
baicalein
chromatographic hydrophobicity index
chrysin
cytotoxic effect
flavonoids
thermal shift assay
Journal
IUBMB life
ISSN: 1521-6551
Titre abrégé: IUBMB Life
Pays: England
ID NLM: 100888706
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
22
12
2019
revised:
30
03
2020
accepted:
14
04
2020
pubmed:
5
5
2020
medline:
9
11
2021
entrez:
5
5
2020
Statut:
ppublish
Résumé
A series of halogenated derivatives of natural flavonoids: baicalein and chrysin were designed and investigated as possible ligands for the catalytic subunit of tumor-associated human kinase CK2. Thermal shift assay method, in silico modeling, and high-performance liquid chromatography-derived hydrophobicity together with IC
Substances chimiques
Antineoplastic Agents
0
Flavanones
0
Flavonoids
0
Protein Kinase Inhibitors
0
chrysin
3CN01F5ZJ5
baicalein
49QAH60606
Casein Kinase II
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250-1261Informations de copyright
© 2020 International Union of Biochemistry and Molecular Biology.
Références
Bortolato A, Cozia G, Moro S. Protein kinase CK2 inhibitors: Emerging anticancer therapeutic agents? Anti-Cancer Agents Med Chem. 2008;8:798-806.
Hanif IM, Hanif IM, Shazib MA, Ahmade KA, Pervaiz S. Casein kinase II: An attractive target for anti-cancer drug design. Int J Biochem Cell Biol. 2010;42:1602-1605.
Buontempo F, McCubrey JA, Orsini E, et al. Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia. 2018;32:1-10.
Chua MMJ, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, et al. CK2 in cancer: Cellular and biochemical mechanisms and potential therapeutic target. Pharmaceuticals. 2017;10:18.
Borgo C, Ruzzene M. Role of protein kinase CK2 in antitumor drug resistance. J Exp Clin Cancer Res. 2019;38:287.
Kim J, Kim SH. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Arch Pharm Res. 2012;35:1293-1296.
Perea SE, Reyes O, Baladron I, Perera Y, Farina H, et al. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo. Mol Cell Biochem. 2012;316:163-167.
Wińska P, Widło Ł, Skierka K, Krzyśko A, Koronkiewicz M, et al. Simultaneous inhibition of protein kinase CK2 and dihydrofolate reductase results in synergistic effect on acute lymphoblastic leukemia cells. Anticancer Res. 2019;39:3531-3542.
Wińska P, Skierka K, Łukowska-Chojnacka E, Koronkiewicz M, Cieśla J, et al. Effect of simultaneous inhibition of protein kinase CK2 and thymidylate synthase in leukemia and breast cancer cells. Anticancer Res. 2018;38:4617-4627.
Buontempo F, Orsini E, Lonetti A, et al. 3232 synergistic cytotoxic effects of bortezomib and CK2 inhibitor cx-4945 in acute lymphoblastic leukemia: Turning off the prosurvival ER chaperone BIP/GRP78 and turning on the proapoptotic NF-κb. Eur J Cancer. 2015;51:S659-S660.
Buontempo F, Orsini E, Lonetti A, et al. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: Turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016;7:1323-1340.
Richter A, Roolf C, Hamed M, et al. Combined casein kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia. BMC Cancer. 2019;19:202.
Song C, Ge Z, Gowda C, Ding Y, Payne J, et al. Abstract 286: Synergistic efficacy of CK2 inhibitor with common chemotherapy drugs by restoring Ikaros function in high-risk ALL. Cancer Res. 2019;79.
Jung J-I, Park K-Y, Kim SA, Kim J. Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells. Biomed Pharmacother. 2018;98:357-363.
Koronkiewicz M, Chilmończyk Z, Kazimierczuk Z. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro. Anticancer Res. 2013;33:4891-4900.
Lewandowska H, Kalinowska M, Lewandowski W, Stępniewski TM, Brzóska K. The role of natural polyphenols in cell signaling and cytoprotection against cancer development. J Nutr Biochem. 2016;32:1-19.
Colomer R, Sarrats A, Lupu R, Puig T. Natural polyphenols and their synthetic analogs as emerging anticancer agents. Curr. Drug Targets. 2017;18:147-159.
Ramos S. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. Mol Nutr Food Res. 2008;52:507-526.
Fresco P, Borges F, Diniz CD, Marques MPM. New insights on the anticancer properties of dietary polyphenols. Med Res Rev. 2006;26:747-766.
Hou D-X, Kumamoto T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: Direct binding and molecular modeling. Antioxid Redox Signal. 2010;13:691-719.
Lamoral-Theys D, Pottier L, Dufrasne F, et al. Natural polyphenols that display anticancer properties through inhibition of kinase activity. Curr Med Chem. 2010;17:812-825.
Guerra B, Issinger O-G. Natural compounds and derivatives as Ser/Thr protein kinase modulators and inhibitors. Pharmaceuticals. 2019;12:4.
Cochet C, Feige JJ, Pirollet M, Keramidas M, Chambaz EM. Selective inhibition of a cyclic nucleotide independent protein kinase (G type casein kinase) by quercetin and related polyphenols. Biochem Pharmacol. 1982;31:1357-1361.
Liu J, Cao X-C, Xiao Q, Quan M-F. Apigenin inhibits HeLa sphere-forming cells through inactivation of casein kinase 2α. Mol Med Rep. 2015;11:665-669.
Tang AQ, Cao XC, Tian L, He L, Liu F. Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3-derived sphere-forming cells. Mol Med Rep. 2015;11:2221-2226.
Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011;10:104.
Lolli G, Cozza G, Mazzorana M, Tibaldi E, Cesero L, et al. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry. 2012;51:6097-6107.
Baier A, Galicka A, Nazaruk J, Szyszka R. Selected flavonoid compounds as promising inhibitors of protein kinase CK2α and CK2 α', the catalytic subunits of CK2. Phytochemistry. 2017;136:39-45.
Baier A, Galicka A, Nazaruk J, Szyszka R. Inhibitory influence of natural flavonoids on human protein kinase CK2 isoforms: Effect of the regulatory subunit. Mol Cell Biochem. 2018;444:35-42.
Pilzys T, Marcinkowski M, Kukwa W, Garbicz D, Dylewska M, et al. New field for anticancer therapy based on ALKBH overexpression in neck and head cancer. Sci Rep. 2019;9:13249.
Zhang L, Wang X-J, Yan Y-J, Xiang W-S. Comparative studies on the interaction of genistein, 8-chlorogenistein, and 3′,8-dichlorogenistein with bovine serum albumin. J Agric Food Chem. 2011;59:7506-7513.
Kay LE, Keifer P, Saarinen T. Pure absorption gradient enhanced heteronuclear single quantum correlation spectroscopy with improved sensitivity. J Am Chem Soc. 1992;114:10663-10665.
Palmer AG III, Cavanagh J, Wright PE, Rance M. Sensitivity improvement in proton-detected two dimensional heteronuclear correlation NMR spectroscopy. J Magn Reson. 1991;93:151-170.
Kontaxis G, Stonehouse J, Laue ED, Keeler J. The sensitivity of experiments which use gradient pulses for coherence pathway selection. J. Magn. Reson., Ser. A. 1994;111:70-76.
Gottlieb HE, Kotlyar V, Nudelman A. NMR chemical shifts of common laboratory solvents as trace impurities. J Org Chem. 1997;62:7512-7515.
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, et al. Gaussian 09, Revision D.01. Wallingford, CT: Gaussian Inc., 2013.
Tomasi J, Mennucci B, Cammi R. Quantum mechanical continuum solvation models. Chem Rev. 2005;105:2999-3093.
Cossi M, Scalmani G, Rega N, Barone V. New developments in the polarizable continuum model for quantum mechanical and classical calculations on molecules in solution. J Chem Phys. 2002;117:43-54.
Mouffok S, Haba H, Lavaud C, Long C, Benkhaled M. Chemical constituents of Centaurea omphalotricha Coss. & Durieu ex Batt. & Trab. Rec Nat Prod. 2012;6:292-295.
Pegg RB, Amarowicz R, Oszmiański J. Confirming the chemical structure of antioxidative trihydroxyflavones from Scutellaria baicalensis using modern spectroscopic methods. Pol J Food Nutr Sci. 2005;55:43-50.
Winiewska M, Kucińska K, Makowska M, Poznański J, Shugar D. Thermodynamics parameters for binding of halogenated benzotriazole inhibitors of human protein kinase CK2 α. Biochim Biophys Acta. 2015;1854:1708-1717.
Eftink MR. The use of fluorescence methods to monitor unfolding transitions in proteins. Biophys J. 1994;66:482-501.
Winiewska-Szajewska M, Płonka D, Zhukov I, Poznański J. Rational drug-design approach supported with thermodynamic studies-A peptide leader for the efficient bi-substrate inhibitor of protein kinase CK2. Sci Rep. 2019;9:11018.
Nevozhay D. Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays. PLoS One. 2014;9:e106186.
Krieger E, Joo K, Lee J, et al. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins. 2009;77:114-122.
Szymaniec-Rutkowska A, Bugajska E, Kasperowicz S, Mieczkowska K, Maciejewska AM, Poznański J. Does the partial molar volume of a solute reflect the free energy of hydrophobic solvation? J Mol Liq. 2019;293:111527.
Mieczkowski A, Bazlekova M, Bagiński M, Wójcik J, Wilczura A, et al. A mild and efficient approach to the 6H-oxazolo[3,2-f]pyrimidine-5,7-dione scaffold via unexpected rearrangement of 2,3-dihydropyrimido[6,1-b][1,5,3]dioxazepine-7,9(5H,8H)-diones: Synthesis, crystallographic studies, and cytotoxic activity screening. Tetrahedron Lett. 2016;57:743-746.
Mieczkowski A, Psurski M, Bagiński M, et al. Novel (S)-1,3,4,12a-tetrahydropyrazino[2,1-c][1,4]benzodiazepine-6,12(2H,11H)-dione derivatives: Selective inhibition of MV-4-11 biphenotypic B myelomonocytic leukemia cells' growth is accompanied by reactive oxygen species overproduction and apoptosis. Bioorg Med Chem Lett. 2018;28:618-625.
Mieczkowski A, Makowska M, Sekuła J, Tomczyk E, Zalewska E, et al. Bicyclic cytarabine analogues: Synthesis and investigation of antitumor properties of novel, 6-aryl- and 6-alkyl-3H-pyrrolo[2,3-d]pyrimidin-2(7H)-one arabinosides. Tetrahedron. 2015;71:8454-8461.
Mieczkowski A, Tomczyk E, Makowska M, Nasulewicz-Goldeman A, Gajda R, et al. The synthesis and investigation of anti-tumor properties of novel, bicyclic furopyrimidine, pyrrolopyrimidine and pyrimidopyridazine nucleoside analogues. Synthesis. 2016;48:566-572.
Mieczkowski A, Wińska P, Kaczmarek M, et al. 2′-Deoxy-2′-azidonucleoside analogs: Synthesis and evaluation of antitumor and antimicrobial activity. Chem Papers. 2018;72:981-990.
Żołnierczyk JD, Olejniczak AB, Mieczkowski A, et al. In vitro antileukemic activity of novel adenosine derivatives bearing boron cluster modification. Bioorg Med Chem. 2016;24:5076-5087.
Liu H, Dong Y, Gao Y, Du Z, Wang Y, et al. The fascinating effects of baicalein on cancer: A review. Int J Mol Sci. 2016;17:E1681.
Guerra B, Bischoff N, Bdzhola VG, et al. A note of caution on ther of halogen bonds for protein kinase/inhibitor recognition suggested by high- and low-salt CK2α complex structures. ACS Chem Biol. 2015;10:1654-1656.
Andres A, Roses M, Rafols C, Bosch E, Espinosa S, et al. Setup and validation of shake-flask procedures for the determination of partition coefficients (log D) from low drug amounts. Eur J Pharm Sci. 2015;76:181-191.
Baier A, Galicka A, Nazaruk J, Szyszka R. Selected flavonoid compounds as promising inhibitors of protein kinase CK2a and CK2a0, the catalytic subunits of CK2. Phytochemistry. 2017;136:39-45.
Yamada M, Katsuma S, Adachi T, Hirasawa A, Shiojima S, et al. Inhibition of protein kinase CK2 prevents the progression of glomerulonephritis. Proc. Natl. Acad. Sci. U.S.A. 2005;102:7736-7741.